Cystic Fibrosis is a lifelong inherited disorder caused by pathogenic variants in the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator protein. CFTR functions as an ion channel and regulator involved in the movement of chloride and bicarbonate across epithelial surfaces. When CFTR function is substantially impaired, salt and water transport becomes abnormal, producing unusually thick and sticky secretions in organs such as the lungs, pancreas and gastrointestinal tract.
In the respiratory system, impaired mucus hydration and clearance allow mucus to accumulate and create an environment conducive to persistent infection and inflammation. Cystic Fibrosis is inherited in an autosomal recessive pattern, meaning that an affected person generally inherits a disease-causing variant from each biological parent.
The molecular basis of Cystic Fibrosis is diverse because many different CFTR variants can impair protein production, processing, channel opening or other aspects of CFTR function. Some variants result in little or no functional CFTR protein, while others produce a protein with reduced activity. This variation contributes to differences in disease presentation and has enabled the development of mutation- or mechanism-informed therapies known as CFTR modulators.
The most common CFTR variant in many European populations is F508del, which primarily affects protein folding and processing, although numerous other variants occur worldwide. The severity and organ distribution of disease are not determined solely by the CFTR genotype; modifier genes, environmental exposures, infections, treatment access and other biological factors can influence clinical outcomes. Genetic testing therefore has both diagnostic and therapeutic relevance.
Respiratory disease is a major component of Cystic Fibrosis. Abnormally viscous airway secretions impair mucociliary clearance, allowing bacteria and other microorganisms to persist within the bronchial tree. Repeated or chronic infection can drive neutrophil-dominated inflammation, airway-wall damage, bronchiectasis and progressive loss of lung function. Organisms associated with CF lung disease can change over time, and chronic colonisation by particular bacteria may be clinically important even when symptoms fluctuate.
Patients may develop persistent cough, sputum production, wheezing, breathlessness and recurrent pulmonary exacerbations. Lung function is commonly monitored with spirometry and other assessments, while imaging can demonstrate structural changes such as bronchiectasis. Respiratory physiotherapy, airway-clearance techniques and appropriately selected antimicrobial treatment are therefore important components of pulmonary care.
Cystic Fibrosis is a multisystem disease rather than a condition confined to the lungs. Reduced CFTR function in the pancreas can impair digestive enzyme delivery to the intestine, causing pancreatic insufficiency, malabsorption and difficulty maintaining adequate nutrition. Treatment may require pancreatic enzyme replacement therapy with meals and snacks, alongside appropriate nutritional support and supplementation of fat-soluble vitamins. The disease can also affect the liver and biliary system, gastrointestinal tract, reproductive system and sweat glands.
Excessive salt concentration in sweat is a defining physiological feature and forms the basis of the sweat chloride test, a major diagnostic investigation. Male infertility is common because congenital absence or severe underdevelopment of the vas deferens can prevent normal sperm transport, although reproductive options may allow some affected men to father biological children.
Diagnosis commonly incorporates newborn screening, sweat chloride testing, molecular analysis and clinical findings. Newborn screening can identify infants at increased likelihood of Cystic Fibrosis before significant symptoms develop, allowing confirmatory testing and early specialist care. The sweat test measures chloride concentration in sweat after stimulation of sweat production, with appropriately interpreted elevated values supporting the diagnosis.
Genetic testing can identify CFTR variants, although detecting variants is not always sufficient by itself to establish or exclude disease because some genetic changes have uncertain clinical significance and not all relevant variants are equally detectable with every assay. Modern diagnostic pathways therefore integrate biochemical, genetic and clinical evidence. Early diagnosis enables nutritional intervention, infection surveillance, vaccination, airway management and consideration of disease-modifying therapies before irreversible organ damage becomes extensive.
Treatment has changed substantially with the development of CFTR modulators, which are medicines designed to improve the function of particular abnormal CFTR proteins. Eligibility depends on the person's specific CFTR variants and the approved indications in the relevant jurisdiction. For respiratory disease, management can include airway-clearance techniques, inhaled therapies, antimicrobial treatment, exercise and monitoring for pulmonary exacerbations. Nutritional management includes pancreatic enzymes where needed, high-energy nutritional strategies and vitamin replacement. Complications such as diabetes related to pancreatic damage may require separate monitoring and treatment. Lung transplantation can be considered for selected people with advanced respiratory failure, although transplantation is not a cure for the underlying genetic condition and involves substantial long-term management.
The natural history of Cystic Fibrosis has changed because of newborn screening, specialist multidisciplinary care, improved antimicrobial strategies, nutritional treatment, airway-clearance methods and CFTR modulators. Historically, severe pulmonary and nutritional complications often resulted in markedly shortened life expectancy, whereas many people diagnosed and treated today can live substantially longer. Outcomes nevertheless vary according to genotype, access to specialised care, socioeconomic circumstances, infection history, organ involvement and response to treatment. Multidisciplinary teams commonly include respiratory physicians, nurses, physiotherapists, dietitians, pharmacists, psychologists and other specialists. Research continues into gene-based approaches, improved CFTR-targeted treatments, infection control and strategies for people whose variants do not respond to currently available modulators.
A common misconception is that Cystic Fibrosis is simply a disease of excessive mucus, but the underlying problem is a defect in epithelial ion transport that has consequences throughout several organ systems. Another misconception is that a person with CF cannot live an active life; many people can participate in education, employment, exercise and family life with appropriate management, although treatment burden can be substantial.
CF is also distinct from a single recurrent chest infection because chronic airway changes and systemic complications arise from the underlying genetic disorder. Modern care increasingly focuses not only on treating symptoms but also on correcting or improving the molecular defect where possible. The disease illustrates how genetic diagnosis, molecular biology, respiratory medicine, nutrition and personalised pharmacology can converge in the management of a complex inherited condition.
